Nanoscope Therapeutics will present four-year follow-up data from its MCO-010 optogenetic gene therapy program in retinitis pigmentosa at the 59th Annual Scientific Meeting of the Retina Society, taking place September 23–26, 2026, in Los Angeles.
Christine Kay, director of clinical research and retinal genetics at Vitreoretinal Associates in Gainesville, Florida, will present the long-term findings from the RESTORE Phase IIb/III trial on September 23.
MCO-010, also known as sonpiretigene isteparvovec and branded as MOGENRY, is an investigational, one-time intravitreal gene therapy designed for patients with retinal degeneration caused by photoreceptor loss. According to Nanoscope, the latest data show that patients treated with the therapy continue to maintain gains in visual acuity four years after treatment.
The company has not yet disclosed the detailed four-year efficacy and safety results, which are expected to be presented at the meeting.
MCO-010 is built on Nanoscope’s multi-characteristic opsin platform, which uses a genetically engineered synthetic opsin to make surviving retinal bipolar cells directly sensitive to light. The approach is intended to bypass damaged or lost photoreceptors while using the retina’s remaining visual circuitry.
Unlike gene therapies developed for specific inherited mutations, MCO-010 is designed to be mutation agnostic and does not require genetic testing before treatment. It is also administered as an in-office intravitreal injection rather than through invasive retinal surgery.
The US FDA recently accepted and filed Nanoscope’s Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa with severe vision loss, bringing the therapy closer to potential regulatory review and commercialization.
The company is also evaluating MCO-010 in other retinal conditions. Phase II data have been generated in Stargardt disease, with a Phase III registrational study planned for 2026. Nanoscope also expects to begin a Phase II program in geographic atrophy and has additional programs in development, including for Leber congenital amaurosis.
MCO-010 has received multiple regulatory designations in the US, Europe, Japan, and Saudi Arabia, including FDA Fast Track and Orphan Drug designations for retinitis pigmentosa and Stargardt disease.
Source: Nanoscope Therapeutics.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
